UNSPSC 51351529: Progesterone caproate

This classification denotes a progestagen with the molecular formula C27H40O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 276F2O42F5, chemically known as pregn-4-ene-3,20-dione, 17-((1-oxohexyl)oxy)-, but more generally known as progesterone caproate, which bears US NIH Compound Identifier 12419. European Medicines Agency schedules progesterone caproate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10076MIG.

Most nations, for tariff purposes, schedule progesterone caproate under HS 29372300. SMILES: CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C.

UNSPSC 51351529 Progesterone caproate is a Commodity code encompassing a single active pharmaceutical ingredient supplied as a finished pharmaceutical product to state and local government health systems, correctional facilities, and other public-sector medical providers. State and local governments procure this product through cooperative purchasing vehicles and multistate agreements that consolidate demand across jurisdictions and negotiate volume pricing with manufacturers and authorized pharmaceutical wholesalers. The work involves manufacturers certifying compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintaining relationships with authorized wholesalers, and supplying products with specified National Drug Codes (NDC), strengths, dosage forms, and packaging configurations to meet the clinical and inventory requirements of participating public health agencies.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products, with a response deadline of March 26, 2026. MMCAP's cooperative vehicle spans Minnesota, Oregon, and other participating jurisdictions; awarded vendors supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with contracts effective July 1, 2026 for a two-year initial term. Evaluation emphasizes price competitiveness (75 percent weight), with additional scoring on fixed pricing, compliance with administrative data formats and EDI capability, and acceptance of a 3 percent administrative fee. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence and maintain contractual relationships with at least two of the three authorized wholesalers, with performance penalties of $200 to $1,500 per violation for late reporting or missed onboarding timelines.